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A commentary on
The role of T3 surface molecules in the
activation of human cells: a two-stimulus
requirement for IL-2 production reflects
events occurring at a pretranslational
level
by Weiss A, Wiskocil R, Stobo J. J Immunol
(1984) 133:123–128.
In 1982, identifying the T cells antigen
receptor was still the elusive “Holy Grail”
of immunology. However, the ability to use
monoclonal antibodies (mAbs) to identify
and characterize molecules on lympho-
cytes, coupled with the then recent abil-
ity to grow long-term antigen-specific T
cell clones, provided a strategy to identify
the TCR by isolating clone-specific mAbs.
We decided to take on this ambitious, but
exciting project.
We set out to grow allo-reactive human
T cell clones with different specificities in
order to use one clone as an immunogen
and other clones with different specifici-
ties as controls. To grow human T cell
clones, a source of growth factors to main-
tain long-term T cell clones was needed
and the recently identified interleukin-2
(IL-2) was the best candidate. However,
human T cells required human IL-2 for
their propagation and it was going to be
cumbersome to stimulate large numbers of
human peripheral blood T cells for a source
of the growth factor. The IL-2 gene had
only recently been cloned and recombinant
IL-2 was not available. However, work from
Gillis and Watson described a human acute
lymphoblastic leukemic T cell line called
Jurkat that could be stimulated with phy-
tohemagglutinin (PHA), a mitogenic plant
lectin reactive with carbohydrates, to pro-
duce IL-2 (1). Stimulating large numbers
of Jurkat cells to produce IL-2 for T cell
cloning purposes offered a simple solution
to our dilemma. We were able to obtain
the Jurkat line from Kendall Smith and
it seemed our problem was solved. PHA
could stimulate the line to produce mod-
erate amounts of bioactive IL-2 and the
amount that it produced could be boosted
by the addition of the tumor promoter,
phorbol myristate acetate (PMA).
Just as we were getting started on the
project, we were dealt a crushing blow by
a paper from Meuer et al., who used T
cell clone specific mAbs to convincingly
identify the TCR (2). They found a clone
specific αβ heterodimer on a human T cell
clone. The identification of the αβ het-
erodimer as the TCR was consistent with
a tumor-specific structure that had pre-
viously been identified by Jim Allison’s
group, who had speculated that the tumor-
specific heterodimer might potentially rep-
resent the TCR (3). Importantly, Meuer
et al. also suggested that the clone-specific
heterodimer that they identified was asso-
ciated with the T3 (later named CD3) com-
plex (2), whose expression was previously
linked to antigen-specific recognition (4).
It had been known for a few years that
mAbs against T3, like PHA, were mitogenic
and could substitute for antigen in induc-
ing T cell activation (5, 6). As we regrouped,
it occurred to us that since Jurkat cells could
be activated by PHA, Jurkat might express
T3 and even an antigen receptor. Indeed,we
found that Jurkat expressed T3 antigens. In
parallel studies, we went on to make clone
specific mAbs to the Jurkat αβ heterodimer,
including the IgM C305 which is a Vβ8 spe-
cific mAb commonly used in Jurkat studies
today (7).
We considered the possibility that Jurkat
might be stimulated via its TCR-T3 com-
plex, but stimulation of the cell with only
anti-T3 mAb resulted in no detectable
secreted IL-2, as assessed by bioassay (note
IL-2 was detected by bioassay using the IL-
2 dependent clone CTLL-20). However, we
found that the addition of PMA, which
had boosted IL-2 production induced by
PHA, converted a negative result into a very
robust positive one (8). The IL-2 response
was highly specific for mAbs to T3 com-
bined with PMA. Moreover, we found this
result to be quite interesting: two stimuli,
one putatively involving a component of
the TCR complex, were required for the
Jurkat line to produce IL-2.
We wondered how these two stimuli
operated in concert to induce IL-2 pro-
duction. Fortunately, we had an experi-
enced molecular biologist in the lab, Bob
Wiskocil, with whom to collaborate to
address this question. Using Northern blot
and dot blot analysis, Bob showed that
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the combination of PHA and PMA could
induce the accumulation of abundant IL-
2 transcripts in Jurkat, whereas PHA alone
induced only low levels of IL-2 RNA (8).
More interestingly, while neither OKT3 (an
anti-T3 mAb) nor PMA induced detectable
IL-2 RNA, the combination induced very
robust accumulation of IL-2 transcripts.
These results suggested that the two stim-
uli operated in concert to regulate the
accumulation of IL-2 RNA.
Our results were consistent with work
in the field involving complex mixtures of
cells that suggested a two-signal require-
ment for IL-2 secretion or for T cell prolif-
eration, but our studies simplified the study
of this phenomenon by utilizing simple
stimuli and a single cell type. Importantly,
it provided a very simple experimental cell
line model to study T cell activation of IL-2
production independently of T cell prolif-
eration. Indeed, the Jurkat model, while
having limitations, has proven extremely
valuable as an experimental tool over the
ensuing years with nearly 16,000 PubMed
references for “Jurkat.” Numerous other
studies have used Jurkat mutants to study
signaling and other phenomena (9). Many
of the proximal molecules involved in TCR
signaling have been either discovered or
validated in the Jurkat system. Moreover,
our results suggested complex regulation
for the IL-2 gene at the transcriptional
level requiring multiple signal inputs, a
notion that has since been well validated
and expanded upon by the variety of sig-
nal inputs that have since been shown
to regulate the IL-2 promoter and its 3 ′
untranslated region (10–12).
The observation that two stimuli could
induce Jurkat to produce IL-2 validated
the concept that stimulation of the TCR
alone was insufficient to activate T cells.
Dating back to 1970, Bretscher and Cohn
had proposed that stimulation of the anti-
gen receptor was insufficient to activate a
naive T cell (13). Much of the early work
on the two-signal model had confounded
the field by the complex mixtures of cells
used and the complexity of the antigens,
second signals, and varied assays used to
assess T cell activation. Our work provided
Jurkat as a simplified T cell model, IL-
2 RNA accumulation or secretion of this
cytokine as a simple output for assessing
activation and a simple stimulus for trig-
gering the TCR. This simple model system
supported the two-signal hypothesis and
elaborated some of the integration of the
two signals at the level of IL-2 gene reg-
ulation. The second signal was not well
addressed by our paper in the Journal of
Immunology. Instead of a physiologic stim-
ulus, we used a small organic molecule,
PMA, to provide the second signal. PMA
had recently been shown to activate a pro-
tein kinase, protein kinase C (PKC) (14),
which was later shown to consist of a fam-
ily of kinases (15). It was also later shown
that PMA also activates the Ras pathway
by virtue of it ability to activate the gua-
nine nucleotide exchanger RasGRP (16).
Abundant work from many labs has well
documented the critical roles for the acti-
vation of PKC and Ras in the pathways
leading to IL-2 gene transcription. A short
time after our Journal of Immunology paper
discussed here, studies from our lab and
from others identified mAbs to Tp44 (later
named re-CD28) on Jurkat and on nor-
mal human T cells as being capable of
delivering the critical second or “costim-
ulatory” signal for the production of IL-2
(17, 18).
The reductionist approach toward
studying T cell activation using the Jurkat
line invigorated the lab and led to an
exciting time of discovery that included
not only studies of the two signal model
of T cell activation, but also included:
(1) the discoveries that stimulation of T3
or the TCR led to an intracellular cal-
cium increase (19, 20); (2) the demon-
stration that the calcium increase in the
cytoplasm was the result of activation of
the inositol phospholipid pathway (21);
and, (3) the discovery that the expres-
sion of the T3 complex required co-
expression of the TCR αβ heterodimer
(7, 22). During these exciting times, we
were joined by several colleagues in the
Stobo lab but most noteworthy were the
contributions of John Imboden and Bob
Wiskocil. We would also like to thank
Kendall Smith for generously providing the
Jurkat cell line that led to an incredible
time of discovery and collegiality in the
Stobo lab.
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